Electroporation for Cancer Treatment Real World Registry
Launched by MIRAI MEDICAL · Jun 10, 2021
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The Electroporation for Cancer Treatment Real World Registry is a study looking at how well certain cancer treatments work in real-life situations for patients with skin or gastrointestinal cancers. Specifically, it focuses on two methods: calcium electroporation and electrochemotherapy. The goal is to see how these treatments affect tumor shrinkage and whether cancer comes back after treatment. The study will also look at any side effects patients may experience and how these side effects relate to the treatments.
Anyone treated with calcium electroporation or electrochemotherapy can participate, as long as they are able to understand the information provided and give written consent. This trial is currently recruiting participants of all ages and genders. If you decide to join, you can expect to share your treatment experiences over time, which will help researchers understand how effective these treatments are and improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient who has been treated using Calcium Electroporation
- • Any patient who has been treated using Electrochemotherapy
- • Patients must be mentally capable of understanding the information given
- • Patients must give written informed consent.
- Exclusion Criteria:
- • None
About Mirai Medical
Mirai Medical is a pioneering clinical trial sponsor dedicated to advancing innovative therapies in the medical field. With a focus on developing cutting-edge solutions for unmet medical needs, Mirai Medical leverages state-of-the-art technology and a robust research framework to streamline the clinical trial process. The organization is committed to enhancing patient outcomes through rigorous scientific methodologies and collaboration with healthcare professionals, ensuring that new treatments are both effective and safe. By fostering partnerships and prioritizing ethical standards, Mirai Medical aims to contribute significantly to the future of healthcare and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
SEAN H Kinsella
Study Director
Mirai Medical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials